These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32816232)

  • 1. Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care.
    Balla S; Ekpo EP; Wilemon KA; Knowles JW; Rodriguez F
    Curr Atheroscler Rep; 2020 Aug; 22(10):60. PubMed ID: 32816232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Brunham LR; Ruel I; Khoury E; Hegele RA; Couture P; Bergeron J; Baass A; Dufour R; Francis GA; Cermakova L; Mancini GBJ; Brophy JM; Brisson D; Gaudet D; Genest J
    Atherosclerosis; 2018 Oct; 277():419-424. PubMed ID: 30270080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
    Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
    J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.
    Amrock SM; Duell PB; Knickelbine T; Martin SS; O'Brien EC; Watson KE; Mitri J; Kindt I; Shrader P; Baum SJ; Hemphill LC; Ahmed CD; Andersen RL; Kullo IJ; McCann D; Larry JA; Murray MF; Fishberg R; Guyton JR; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Underberg JA; Thompson P; Duffy D; Linton MF; Shapiro MD; Moriarty PM; Knowles JW; Ahmad ZS
    Atherosclerosis; 2017 Dec; 267():19-26. PubMed ID: 29080546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Lalić K; Rajković N; Popović L; Lukač SS; Stošić L; Rasulić I; Lalić NM
    Atherosclerosis; 2018 Oct; 277():298-303. PubMed ID: 30270062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
    Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
    J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry.
    Kayıkcioglu M; Başaran Ö; Doğan V; Mert KU; Mert GÖ; Özdemir İH; Rencüzoğulları İ; Karadeniz FÖ; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Cinier G; Akay KH; Pekel N; Utku Şenol ; Demir V; İnci S; Derviş E; Özlek B; Özlek E; Çelik O; Çil C; Biteker M
    J Clin Lipidol; 2023; 17(6):732-742. PubMed ID: 38072583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial Hypercholesterolemia: Global Burden and Approaches.
    Tokgozoglu L; Kayikcioglu M
    Curr Cardiol Rep; 2021 Sep; 23(10):151. PubMed ID: 34480646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.